{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:04:39Z","timestamp":1779753879542,"version":"3.53.1"},"reference-count":14,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Contact Dermatitis"],"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Tapinarof cream 1% is a novel, non\u2010steroidal topical aryl hydrocarbon receptor\u2010modulating agent approved for the treatment of plaque psoriasis and atopic dermatitis (AD). There has only been one report of allergic sensitization to tapinarof cream.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n This study aimed to determine whether tapinarof cream\u2010induced contact dermatitis represents an allergic or irritant reaction, and to identify the causative allergen in allergic cases.<\/jats:p>\n <\/jats:sec>\n \n Patients\/Methods<\/jats:title>\n \n Nine patients (seven with psoriasis and two with AD) who developed contact dermatitis during treatment with tapinarof cream were included. Patch testing was performed with the cream\n as is<\/jats:italic>\n ; tapinarof at concentrations of 1%, 0.3%, and 0.1% in petrolatum; and two additives (propylene glycol 10% aqueous solution and disodium edetate hydrate 1% in petrolatum).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Patch testing with tapinarof cream\n as is<\/jats:italic>\n was positive in four patients with psoriasis and both patients with AD. All six patients also showed dose\u2013response relationships with tapinarof, increasing from 0.1% to 1%. The remaining three patients with psoriasis showed negative patch test results to both the cream\n as is<\/jats:italic>\n and its individual components.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Tapinarof cream\u2010induced contact dermatitis may present as either an allergic or irritant reaction. In all six allergic cases, tapinarof was strongly suggested to be the causative allergen.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/cod.70191","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T23:55:02Z","timestamp":1779753302000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tapinarof as a Likely Contact Allergen: Evidence From Patch Testing of Allergic and Irritant Contact Dermatitis"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-7064","authenticated-orcid":false,"given":"Shigeruko","family":"Iijima","sequence":"first","affiliation":[{"name":"Division of Dermatology Hanamizuki Clinic Ibaraki Japan"},{"name":"Department of Dermatology Ryugasaki Saiseikai Hospital Ibaraki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Murayama","sequence":"additional","affiliation":[{"name":"Division of Dermatology Hanamizuki Clinic Ibaraki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Takayama","sequence":"additional","affiliation":[{"name":"Division of Dermatology Hanamizuki Clinic Ibaraki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-3006","authenticated-orcid":false,"given":"Kayoko","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"General Incorporated Association SSCI\u2010Net Nagoya Japan"},{"name":"Fujita Health University Toyoake Japan"},{"name":"Department of Dermatology and Allergy Kariya Orthopedic Hospital Kariya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"StatPearls","author":"Elder A. J.","year":"2024"},{"issue":"24","key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis","volume":"385","author":"Lebwohl M. G.","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/1346-8138.17423","article-title":"Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety Results From 2 Japanese Phase 3 Trails","volume":"51","author":"Igarashi A.","year":"2024","journal-title":"Journal of Dermatology"},{"issue":"3","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","article-title":"Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2\u2009Years of Age in the Pivotal Phase 3 ADORING Trials","volume":"91","author":"Silverberg J. I.","year":"2024","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"11","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/1346-8138.17451","article-title":"Tapinarof Cream for the Treatment of Atopic Dermatitis: Efficacy and Safety Results From Two Japanese Phase 3 Trails","volume":"51","author":"Igarashi A.","year":"2024","journal-title":"Journal of Dermatology"},{"issue":"6","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/cod.14535","article-title":"Case Report: Contact Allergy to Tapinarof","volume":"90","author":"Scheman A.","year":"2024","journal-title":"Contact Dermatitis"},{"issue":"5","key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/derm.2024.0365","article-title":"Clarification and Modification of the International Contact Dermatitis Research Group Classification of Patch Test Reactions on Behalf of the International Contact Dermatitis Research Group","volume":"36","author":"Bruze M.","year":"2025","journal-title":"Dermatitis"},{"issue":"1","key":"e_1_2_10_9_1","article-title":"Characteristics and Management of Follicular Events and Contact Dermatitis in Patients Using Tapinarof Cream for the Treatment of Atopic Dermatitis or Plaque Psoriasis","volume":"36","author":"Gold L. S.","year":"2025","journal-title":"Journal of Dermatological Treatment"},{"key":"e_1_2_10_10_1","first-page":"1056","volume-title":"Monographs in Contact Allergy, Volume 1: Non\u2010Fragrance Allergens in Cosmetics","author":"Groot A. C.","year":"2018"},{"issue":"21","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215424","article-title":"Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis","volume":"20","author":"Furue M.","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26041618","article-title":"The Aryl Hydrocarbon Receptor (AHR): Peacekeeper of the Skin","volume":"26","author":"Dawe H.","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"issue":"10","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof Is a Natural AhR Agonist That Resolves Skin Inflammation in Mice and Humans","volume":"137","author":"Smith S. H.","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"6","key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jid.2020.11.024","article-title":"Cyp 1A1 Enzymatic Activity Influences Skin Inflammation via Regulation of the AHR Pathway","volume":"141","author":"Kyoreva M.","year":"2021","journal-title":"Journal of Investigative Dermatology"},{"issue":"2","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11020227","article-title":"AHR and NRF2 in Skin Homeostasis and Atopic Dermatitis","volume":"11","author":"Edamitsu T.","year":"2022","journal-title":"Antioxidants"}],"container-title":["Contact Dermatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cod.70191","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cod.70191","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cod.70191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T23:55:04Z","timestamp":1779753304000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cod.70191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":14,"alternative-id":["10.1111\/cod.70191"],"URL":"https:\/\/doi.org\/10.1111\/cod.70191","archive":["Portico"],"relation":{},"ISSN":["0105-1873","1600-0536"],"issn-type":[{"value":"0105-1873","type":"print"},{"value":"1600-0536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"2026-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"cod.70191"}}